autologous Tris-CAR-T cell therapy (Tasly Pharmaceutical Group/Beijing Tiantan Hospital)

N/A

Report date: 2025/03/14 16:35:56

Base Information

Drug Nameautologous Tris-CAR-T cell therapy (Tasly Pharmaceutical Group/Beijing Tiantan Hospital)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionInterleukin-7 receptors modulatorsCD44 antigen modulatorsCD133 modulators
TargetsCD133Interleukin-7 receptorsCD44 antigen
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesTianjin Tasly Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Tiantan Hospital, Capital Medical UniversityTianjin Tasly Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A